Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine- and choline-deficient diet

Experimental and Therapeutic Medicine

Volumn 7, Issue 3, 2014, Pages 663-668

  Wang, Yunliang ^a   Li, Jian ^a   Zhuge, Li ^a   Su, Dongmei ^a   Yang, Meijuan ^a   Tao, Shiying ^a   Li, Junxiang ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Curcumin; Nuclear factor B; Peroxisome proliferator activated receptor ; Puerarin; Steatohepatitis

Indexed keywords

EID: 84893018584     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1461     Document Type: Article

References (35)

1. Williamson RM, Price JF, Glancy S, et al; Edinburgh Type 2 Diabetes Study Investigators: Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 34: 1139-1144, 2011.
2. Valantinas J, Apanaviciene DA, Maroziene L and Sveikata A: The prevalence of metabolic risk factors among outpatients with diagnosed nonalcoholic fatty liver disease in Lithuania. Med Sci Monit 18: PH57-PH62, 2012.
3. Chitturi S and Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21: 27-41, 2001.
4. Reid AE: Nonalcoholic steatohepatitis. Gastroenterology 121: 710-723, 2001.
5. Kallwitz ER, McLachlan A and Cotler SJ: Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 14: 22-28, 2008.
6. Wu CW, Chu ES, Lam CN, et al: PPARgamma is essential for protection against nonalcoholic steatohepatitis. Gene Ther 17: 790-798, 2010.
7. Yuhas Y, Berent E, Cohen R and Ashkenazi S: Roles of NF-kappaB activation and peroxisome proliferator-activated receptor gamma inhibition in the effect of rifampin on inducible nitric oxide synthase transcription in human lung epithelial cells. Antimicrob Agents Chemother 53: 1539-1545, 2009.
8. Sanyal AJ, Mofrad PS, Contos MJ, et al: A pilot study of vitaminE versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2: 1107-1115, 2004.
9. Promrat K, Lutchman G, Uwaifo GI, et al: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39: 188-196, 2004.
10. Elasy TA and Griffin M: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association: response to Nesto. Diabetes Care 27: 2096, 2004.
11. Nesto RW, Bell D, Bonow RO, et al: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27: 256-263, 2004.
12. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR and Fonseca VA: Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134: 61-71, 2001.
13. Seeff LB, Lindsay KL, Bacon BR, Kresina TF and Hoofnagle JH: Complementary and alternative medicine in chronic liver disease. Hepatology 34: 595-603, 2001.
14. Ghosh N, Ghosh R, Mandal V and Mandal SC: Recent advances in herbal medicine for treatment of liver diseases. Pharm Biol 49: 970-988, 2011.
15. Yao QH, Wang DQ, Cui CC, et al: Curcumin ameliorates left ventricular function in rabbits with pressure overload: inhibition of the remodeling of the left ventricular collagen network associated with suppression of myocardial tumor necrosis factor-alpha and matrix metalloproteinase-2 expression. Biol Pharm Bull 27: 198-202, 2004.
16. Vizzutti F, Provenzano A, Galastri S, et al: Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest 90: 104-115, 2010.
17. Tang Y, Zheng S and Chen A: Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology 150: 3011-3020, 2009.
18. Xiao C, Li J, Dong X, et al: Anti-oxidative and TNF-α suppressive activities of puerarin derivative (4AC) in RAW264.7 cells and collagen-induced arthritic rats. Eur J Pharmacol 666: 242-250, 2011.
19. Zheng P, Ji G, Ma Z, et al: Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways. Am J Chin Med 37: 69-83, 2009.
20. Chung MJ, Sung NJ, Park CS, et al: Antioxidative and hypocholesterolemic activities of water-soluble puerarin glycosides in HepG2 cells and in C57 BL/6J mice. Eur J Pharmacol 578: 159-170, 2008.
21. Xiao LZ, Gao LJ and Ma SC: Comparative study on effects of puerarin and granulocyte colony-stimulating factor in treating acute myocardial infarction. Zhongguo Zhong Xi Yi Jie He Za Zhi 25: 210-213, 2005 (In Chinese).
22. Dowman JK, Tomlinson JW and Newsome PN: Pathogenesis of non-alcoholic fatty liver disease. QJM 103: 71-83, 2010.
23. Fon Tacer K and Rozman D: Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids 2011: 783976, 2011.
24. Day CP and James OF: Steatohepatitis: a tale of two 'hits'? Gastroenterology, 114: 842-845, 1998.
25. Postic C and Girard J: Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829-838, 2008.
26. Kugelmas M, Hill DB, Vivian B, Marsano L and McClain CJ: Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38: 413-419, 2003.
27. Tilg H and Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343: 1467-1476, 2000.
28. Tarantino G, Conca P, Pasanisi F, et al: Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 21: 504-511, 2009.
29. Cai D, Yuan M, Frantz DF, et al: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11: 183-190, 2005.
30. Gaemers IC and Groen AK: New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr Opin Lipidol 17: 268-273, 2006.
31. Reddy JK: Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 281: G1333-G1339, 2001.
32. Anstee QM and Goldin RD: Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87: 1-16, 2006.
33. Vance JE and Vance DE: The role of phosphatidylcholine biosynthesis in the secretion of lipoproteins from hepatocytes. Can J Biochem Cell Biol 63: 870-881, 1985.
34. Yao ZM and Vance DE: The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J Biol Chem 263: 2998-3004, 1988.
35. Gyamfi MA, Damjanov I, French S and Wan YJ: The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem Pharmacol 75: 981-995, 2008.